Immunotherapy for the Treatment of Urothelial Carcinoma

The Journal of Urology; January 2017; Volume 197, Issue 1, Pages 14–22 Donin NM1, Lenis AT1, Holden S1, Drakaki A1, Pantuck A1, Belldegrun A1, Chamie K2. 1 Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine at UCLA, Los … Continue reading

Posted in Publications, Uncategorized | Leave a comment

Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility

Urol Oncol. 2017 Jan 3. Donin NM1, Strauss-Ayali D2, Agmon-Gerstein Y2, Malchi N2, Lenis AT3, Holden S3, Pantuck AJ4, Belldegrun AS4, Chamie K4. 1Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, CA. 2UroGen Pharma Ltd., … Continue reading

Posted in Publications, Uncategorized | Leave a comment

Pharmacokinetic, Pharmacodynamic, and Activity Evaluation of TMX-101 in a Multicenter Phase 1 Study in Patients With Papillary Non-Muscle-Invasive Bladder Cancer.

Clinical Genitourinary Cancer 2015;13(3):204-9.e2. Arends TJ, Lammers RJ, Falke J, van der Heijden AG, Rustighini I, Pozzi R, Ravic M, Eisenhardt A, Vergunst H, Witjes JA. INTRODUCTION/BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a strong tendency to recur despite adjuvant instillations. TMX-101 … Continue reading

Posted in Publications, Uncategorized | Leave a comment

Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.

The Journal of Urology 2013;189(6):2077–82. Falke JJ, Lammers RJ, Arentsen HC, Ravic M, Possi R, Cornel EB, Vergunst H, deReijke TM, Witjes JA. PURPOSE: Imiquimod, a toll like receptor 7 (TLR-7) agonist, is effective as a topical treatment for skin malignancies. … Continue reading

Posted in Publications, Uncategorized | Leave a comment